Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

• Forschungsstelle: INNOSUISSE
• Projektnummer: 59256.1 IP-LS
• Projekttitel Englisch: Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Kurzbeschreibung (Deutsch)

Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Kurzbeschreibung (Englisch)

Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Abstract (Deutsch)

In this project PharmaBiome#s Functional Consortium (PB-FC) designed for the treatment of gut dysbiosis in acute graft-versus-host disease (aGvHD) patients will be tested in mouse models to answer essential questions for the successful translation of our novel, function-based approach.